14 September 2017  
EMA/CHMP/595185/2017  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Tasigna 
nilotinib 
On 14 September 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Tasigna. The marketing authorisation holder for this medicinal product is Novartis Europharm Ltd. 
The CHMP adopted an extension to the existing indication as follows:2 
“Tasigna is indicated for the treatment of: 
 
adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic 
myelogenous leukaemia (CML) in the chronic phase, 
 
adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with 
resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in 
blast crisis are not available, 
  paediatric patients with chronic phase Philadelphia chromosome positive CML with 
resistance or intolerance to prior therapy including imatinib.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
                                                
